Contact Us: 734-712-3456
Media Contact:
Laura Blodgett, Media Relations
Saint Joseph Mercy Health System

SJMAA Enrolls First Patient in Investigational Treatment for Challenging Hypertension
Start Date

St. Joseph Mercy Ann Arbor Enrolls First Patient in Landmark Study to Evaluate Investigational Treatment for Challenging Hypertension

St. Joseph Mercy Ann Arbor is accepting patients for national clinical trial

St. Joseph Mercy Ann Arbor is enrolling patients into a national clinical trial evaluating a novel procedure for difficult-to-treat high blood pressure (also called treatment-resistant hypertension).  The study, SYMPLICITY HTN-3, is a landmark clinical trial evaluating the investigational Symplicity® renal denervation system.

Treatment-resistant hypertension, defined as high blood pressure despite treatment with three or more blood pressure lowering medications, poses a serious health threat to nearly nine million Americans.

Treatment-resistant hypertension is an especially dangerous chronic disease because of its association with increased risk for stroke, heart attack, heart failure and kidney disease. Research suggests that as many as 28 percent of treated individuals with high blood pressure are considered resistant to treatment. Additionally, these patients have a threefold increase in the risk of cardiovascular events compared with individuals with controlled high blood pressure.

Renal denervation is a minimally invasive, catheter-based procedure that delivers radiofrequency energy to interfere with the nerves that line the walls of the kidney arteries. These nerves are part of the sympathetic nervous system, and in people with high blood pressure (hypertension), the renal nerves are hyperactive, raising blood pressure and contributing to heart, kidney and blood vessel damage.

“We are thrilled to participate in the SYMPLICITY HTN-3 study of renal denervation.  SYMPLICITY HTN-3 is evaluating an innovative approach to treating the growing population of people with resistant hypertension in the United States,” said Herbert D. Aronow, MD, MPH site principal investigator for the study. “The addition of renal denervation to ongoing treatment with blood pressure medications has the potential to help patients with this challenging form of hypertension achieve their target blood pressure levels.”

In all, the study plans to enroll approximately 530 treatment-resistant hypertension patients across 90 U.S. medical centers. People receiving the investigational treatment will be compared with a control group that undergoes a sham or 'fake' procedure while under sedation, with all patients continuing to take their blood pressure medications; patients enrolled in the SYMPLICITY HTN-3 trial will be randomly assigned to a group. The primary endpoints of the study are the change in blood pressure from baseline to six months and incidence of major adverse events. 

The first St. Joseph Mercy Ann Arbor patient who was part of the trial passed all necessary preliminary evaluations in order to participate in the trial.  Because this was a blinded trial, the hospital and its investigator cannot discuss whether the patient underwent a sham procedure or the renal sympathetic denervation procedure.

“The patient did extremely well and was excited to be a part of this groundbreaking study. The patient hopes the results will not only be life changing for them, but also offer progress toward better treatment for others who suffer from treatment-resistant hypertension,” commented Aronow. “We intend to enroll many more patients in this study as we collectively search for new treatment paradigms for patients suffering from severe hypertension.”

St. Joseph Mercy Ann Arbor is actively recruiting patients for the trial. Those interested in more information call 734-712-7602.